PRMT1 Inhibitor Compounds Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective inhibitors for the disease-associated chromatin-modifying enzyme PRMT1, which plays a role in various disorders such as proliferative, autoimmune, muscular, vascular, neurological, and metabolic disorders, necessitating the development of small molecules that can specifically inhibit PRMT1 activity.
Innovation Solution
Compounds of a specific formula, or their pharmaceutically acceptable salts, are used to inhibit PRMT1 activity, offering selectivity over other methyltransferases and potential therapeutic benefits in treating PRMT1-mediated disorders by modulating gene expression and protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used, then existing therapeutic options are available, but effective inhibition of PRMT1 activity is not achieved
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (Formula I) that create localized interactions with PRMT1's active site. The molecular structure includes specific functional groups and spatial arrangements that enable selective binding to PRMT1 while excluding other methyltransferases, thus achieving both efficacy and selectivity simultaneously.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the compounds (such as substituent groups, molecular weight, and structural configuration) to optimize the balance between PRMT1 inhibition potency and selectivity. This allows tuning of the compound properties to achieve the desired therapeutic window.
2Adaptability or versatility
If broad-spectrum methyltransferase inhibitors are used, then multiple enzyme targets are covered, but specific PRMT1 inhibition is not achieved
Solution Approach 1:
Instead of designing a broad-spectrum inhibitor that accidentally hits PRMT1, the patent inverts the approach by specifically designing compounds that target PRMT1's unique structural features. This selective design strategy achieves high PRMT1 inhibition efficacy while maintaining the ability to differentiate from other methyltransferases.
3Ease of manufacture
If no specific PRMT1 inhibitors are available, then existing treatments can be used, but therapeutic benefits for PRMT1-mediated disorders cannot be realized
Solution Approach 1:
The patent applies preliminary action by developing and characterizing a series of PRMT1 inhibitor compounds before clinical application. The compounds of Formula I are designed, synthesized, and validated in advance to ensure they meet the necessary efficacy and selectivity criteria, making them ready for therapeutic use in PRMT1-mediated disorders.
Data Source
AI summary
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.